title: Fibrate-associated adverse effects beyond muscle and liver toxicity.
abstract: Fibrate derivatives have a 40-year history in the management of dyslipidemia. Although this class of drugs is generally well tolerated, several safety issues have arisen from their use. In the present article we review the literature describing side effects associated with the use of fibrates except for those that are liver and muscle related. These effects are less well known but are clinically relevant.
authors.affiliation: Department of Internal Medicine, Medical School, University of Ioannina, Ioannina 45110, Greece.
authors.forename: M
authors.initials: M
authors.lastname: Florentin
authors.forename: E N
authors.initials: EN
authors.lastname: Liberopoulos
authors.forename: D P
authors.initials: DP
authors.lastname: Mikhailidis
authors.forename: M S
authors.initials: MS
authors.lastname: Elisaf
mesh_terms: D000818:Animals; D056486:Chemical and Drug Induced Liver Injury; D002986:Clinical Trials as Topic / Q000379:methods; D002995:Clofibric Acid / Q000009:adverse effects* / Q000737:chemistry; D006801:Humans; D008107:Liver Diseases / Q000453:epidemiology / Q000473:pathology; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000473:pathology; D009135:Muscular Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology
chemical_list: D002995:Clofibric Acid